Last reviewed · How we verify

NCT05868486

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

Active, enrolled EARLY_PHASE1 Last updated 2 January 2026
What this trial tests

EARLY_PHASE1 trial testing Biospecimen Collection in Hematopoietic and Lymphoid System Neoplasm in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 May 2022
Primary endpoint
19 October 2026
19 October 2026

Quick facts

Lead sponsorCity of Hope Medical Center
PhaseEARLY_PHASE1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment100
Start date20 May 2022
Primary completion19 October 2026
Estimated completion19 October 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Hematopoietic and Lymphoid System Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Feasibility of a cancer screening program using multicancer early detection testing and whole-body magnetic resonance imaging in a high-risk population.
    Raz DJ, Nehoray B, Ceniceros A, Motarjem P, et al · · 2025 · PMID 39748640 · DOI 10.1002/cncr.35709

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

Other recruiting trials for Hematopoietic and Lymphoid System Neoplasm

Currently open trials in the same condition.

Other City of Hope Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05868486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing